866-997-4948(US-Canada Toll Free)

Peritoneal Tumor - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 69 Pages

Peritoneal Tumor - Pipeline Review, H1 2014

Summary

Global Markets Directs, Peritoneal Tumor - Pipeline Review, H1 2014, provides an overview of the Peritoneal Tumors therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peritoneal Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Tumor and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peritoneal Tumor
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peritoneal Tumor and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peritoneal Tumor pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Tumor
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peritoneal Tumor pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Peritoneal Tumor Overview 6
Therapeutics Development 7
Pipeline Products for Peritoneal Tumor Overview 7
Pipeline Products for Peritoneal Tumor Comparative Analysis 8
Peritoneal Tumor Therapeutics under Development by Companies 9
Peritoneal Tumor Therapeutics under Investigation by Universities/Institutes 11
Peritoneal Tumor Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Peritoneal Tumor Products under Development by Companies 14
Peritoneal Tumor Products under Investigation by Universities/Institutes 15
Peritoneal Tumor Companies Involved in Therapeutics Development 16
Boehringer Ingelheim GmbH 16
Amgen Inc. 17
Eli Lilly and Company 18
Cell Therapeutics, Inc. 19
MEI Pharma, Inc. 20
Recepta Biopharma S.A. 21
AbbVie Inc. 22
Peritoneal Tumor Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 27
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
trebananib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
paclitaxel poliglumex - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
idronoxil - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ramucirumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RebmAb-100 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
nintedanib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ABT-767 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53

List of Table

List of Tables
Number of Products under Development for Peritoneal Tumor, H1 2014 7
Number of Products under Development for Peritoneal Tumor Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Peritoneal Tumor Pipeline by Boehringer Ingelheim GmbH, H1 2014 16
Peritoneal Tumor Pipeline by Amgen Inc., H1 2014 17
Peritoneal Tumor Pipeline by Eli Lilly and Company, H1 2014 18
Peritoneal Tumor Pipeline by Cell Therapeutics, Inc., H1 2014 19
Peritoneal Tumor Pipeline by MEI Pharma, Inc., H1 2014 20
Peritoneal Tumor Pipeline by Recepta Biopharma S.A., H1 2014 21
Peritoneal Tumor Pipeline by AbbVie Inc., H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Peritoneal Tumor Therapeutics Recent Pipeline Updates, H1 2014 56
Peritoneal Tumor Dormant Projects, H1 2014 63
Peritoneal Tumor Discontinued Products, H1 2014 64

List of Chart

List of Figures
Number of Products under Development for Peritoneal Tumor, H1 2014 7
Number of Products under Development for Peritoneal Tumor Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *